Literature DB >> 19224901

Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation.

B O Bachmann1, E Luetjen-Drecoll, F Bock, S J Wiegand, D Hos, R Dana, F E Kruse, C Cursiefen.   

Abstract

BACKGROUND: High-risk keratoplasties are usually performed after an uninflamed and quiescent interval in corneas with partly regressed blood and lymphatic vessels. We analysed whether the inhibition of post-keratoplasty revascularisation in mice with partly regressed corneal vessels ("intermediate-risk") improves graft survival.
METHODS: Three interrupted stromal sutures (11-0) in corneas of Balb/c mice (6-8 weeks old) were placed for 6 weeks. Six months after suture removal, penetrating keratoplasty was performed with C57BL/6 donors. The treatment group received a vascular endothelial growth factor-A specific cytokine trap (VEGF Trap) intraperitoneally at days 0, 4, 7 and 14 after keratoplasty (25 mg/kg per mouse; controls received equal amounts of Fc protein). Pathological haemangiogenesis and lymphangiogenesis prior to as well as 3 days or 8 weeks after keratoplasty and graft survival were analysed.
RESULTS: Three days after keratoplasty corneal revascularisation was sufficiently reduced by VEGF Trap (haem-vascularised areas 42.7% reduction; lymph-vascularised areas 54.7% reduction). Survival proportions 8 weeks after keratoplasty were 36% in the treatment group compared with 9% in the control group (n = 11; p<0.05). At that time no differences in haemangiogenesis or lymphangiogenesis were observed between the two groups.
CONCLUSION: Early transient postoperative induction of haemangiogenesis and lymphangiogenesis and reformation of regressed corneal blood and lymphatic vessels are important for transplant rejections after "intermediate-risk" corneal transplantation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224901     DOI: 10.1136/bjo.2008.145128

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  16 in total

1.  [Bevacizumab goes anterior: antiangiogenic therapy at cornea and conjunctiva].

Authors:  C Cursiefen
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

Review 2.  [Antiangiogenic therapy at the ocular surface: when, what and why?].

Authors:  F Bock; B Regenfuss; C Cursiefen
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059

3.  Effect of sorafenib in a murine high risk penetrating keratoplasty model.

Authors:  Yang Kyung Cho; Eun Young Shin; Hironori Uehara; Balamurali K Ambati
Journal:  Int J Ophthalmol       Date:  2017-06-18       Impact factor: 1.779

4.  Comparative evaluation of lymphatic vessels in primary versus recurrent pterygium.

Authors:  S Ling; Q Li; H Lin; W Li; T Wang; H Ye; J Yang; X Jia; Y Sun
Journal:  Eye (Lond)       Date:  2012-09-14       Impact factor: 3.775

5.  Kinetics of Angiogenic Responses in Corneal Transplantation.

Authors:  Takenori Inomata; Alireza Mashaghi; Antonio Di Zazzo; Sang-Mok Lee; Homer Chiang; Reza Dana
Journal:  Cornea       Date:  2017-04       Impact factor: 2.651

6.  Efficacy of topical bevacizumab in high-risk corneal transplant survival.

Authors:  Nasir Bhatti; Umair Qidwai; Munawar Hussain; Asif Kazi
Journal:  Pak J Med Sci       Date:  2013-04       Impact factor: 1.088

7.  Novel approach for a PTX/VEGF dual drug delivery system in cardiovascular applications-an innovative bulk and surface drug immobilization.

Authors:  Katharina Wulf; Michael Teske; Claudia Matschegewski; Daniela Arbeiter; Dalibor Bajer; Thomas Eickner; Klaus-Peter Schmitz; Niels Grabow
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

Review 8.  Corneal neovascularization: an anti-VEGF therapy review.

Authors:  Jin-Hong Chang; Nitin K Garg; Elisa Lunde; Kyu-Yeon Han; Sandeep Jain; Dimitri T Azar
Journal:  Surv Ophthalmol       Date:  2012-09       Impact factor: 6.048

Review 9.  Corneal lymphangiogenesis in herpetic stromal keratitis.

Authors:  Paul J Park; Michael Chang; Nitin Garg; Jimmy Zhu; Jin-Hong Chang; Deepak Shukla
Journal:  Surv Ophthalmol       Date:  2014-06-10       Impact factor: 6.048

10.  Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival.

Authors:  Mohammad H Dastjerdi; Daniel R Saban; Andre Okanobo; Nambi Nallasamy; Zahra Sadrai; Sunil K Chauhan; Amir R Hajrasouliha; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-05       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.